Acquisition of APIRx

For personal use only Benefits of the APIRx Acquisition 01. Substantial IP portfolio covering active pharmaceutical ingredients, formulations and methods of use to secure commercial exclusivity. Developed technologies and IP at all stages of cannabinoid drug development from extraction to therapeutic uses. 02. Clinical stage: Proof of concept and formulations have been established for APIRX drug products. - Multiple completed pre-clinical, phase 1 and phase 2 clinical trials. Favorable interactions with the FDA and other major regulators. Several pre-IND meetings completed and INDS open. 03. Diversified portfolio of treatment solutions will expand our global addressable market opportunity by over US$ 400B per annum. Incannex 04. Potential for short runways to market by leveraging public data on existing FDA or EMA registered pharmaceutical cannabinoid products Sativex and Marinol. (owned by Jazz Pharmaceuticals, formerly GW Pharmaceuticals, and AbbVie Inc respectively) Short pathway to registration and commercial launch for MedChew™ Rx and MedChew™ Dronabinol, as the active pharmaceutical ingredient is the same as approved products but with a novel dosage form (medicated chewing gum for increased bioavailability and extended release). Discussions with regulatory agencies for registration will focus on a request for a single bridging clinical trial for MedChew™ Rx and MedChew™ Dronabinol. 05. Commercially exclusive patented drug delivery technologies expand potential applications for established compounds and IHL-675A multi-use anti-inflammatory cannabinoid combination drug. Some of these technologies include: Medicated chewing gums and chewable tablets. High bioavailability oral mucosa delivery mechanisms. Super slow-release delivery formulations. Topical and ophthalmic formulations. Shareholder Presentation LO 5

View entire presentation